2020
Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond
Srivastava A, Patel HV, Kim S, Shinder B, Sterling J, Tabakin AL, Polotti CF, Saraiya B, Mayer T, Kim IY, Ghodoussipour S, Patel HD, Jang TL, Singer EA. Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond. Urologic Oncology Seminars And Original Investigations 2020, 39: 247-257. PMID: 33223368, PMCID: PMC7574787, DOI: 10.1016/j.urolonc.2020.10.012.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaUpstaging riskOverall survivalCell carcinomaNonclear cell renal cell carcinomaOrgan-confined renal cell carcinomaCox proportional hazards modelNational Cancer DatabaseCell renal cell carcinomaKaplan-Meier curvesProportional hazards modelSmall renal massesCOVID-19Logistic regression modelsPT3a upstagingDelaying surgeryPrimary endpointSecondary endpointsPatient comorbiditiesMeier curvesElective surgeryRadical nephrectomyTumor histologyClinical stageRCC patients
2018
Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer
Yuh B, Kwon Y, Shinder B, Singer E, Jang T, Kim S, Stein M, Mayer T, Ferrari A, Lee N, Parikh R, Ruel N, Kim W, Horie S, Byun S, Ahlering T, Kim I. Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer. Prostate International 2018, 7: 102-107. PMID: 31485434, PMCID: PMC6713798, DOI: 10.1016/j.prnil.2018.10.002.Peer-Reviewed Original ResearchMetastatic prostate cancerCytoreductive radical prostatectomyPhase 1 studyProstate-specific antigenRadical prostatectomyCytoreductive surgeryProstate cancerSpecific antigenDeath 5 monthsAcute tubular necrosisMajor perioperative complicationsOverall complication rateRapid disease progressionDay of surgerySubset of menPerioperative complicationsPrimary endpointTemporary dialysisComplication rateDisseminated diseaseTubular necrosisMajor complicationsMean ageClinical trialsDisease progression